Public Profile

Orexo Us, Inc.

Orexo US, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 1995, the company has established itself as a leader in developing innovative treatments for opioid dependence and pain management. Orexo is renowned for its unique drug delivery systems, particularly its sublingual formulations that enhance patient compliance and therapeutic outcomes. With a strong focus on addressing unmet medical needs, Orexo has achieved significant milestones, including the successful launch of its flagship product, Zubsolv, which has garnered recognition for its effectiveness in treating opioid use disorder. The company’s commitment to research and development positions it favourably in the competitive landscape, making Orexo US, Inc. a key contributor to advancements in addiction treatment and pain relief solutions.

DitchCarbon Score

How does Orexo Us, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Orexo Us, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

0%

Let us know if this data was useful to you

Orexo Us, Inc.'s reported carbon emissions

Orexo Us, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the company may be engaged in broader industry initiatives aimed at sustainability and reducing environmental impact. As the pharmaceutical sector increasingly focuses on climate action, Orexo Us, Inc. may align with these trends in the future. For now, details regarding their specific emissions or climate strategies remain unspecified.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Orexo Us, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Orexo Us, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Orexo Us, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Amneal

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Indivior, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Aquestive Therapeutics, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

BioDelivery Sciences International, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Teva Pharmaceuticals

IL
Pharmaceutical Preparation Manufacturing
Updated about 20 hours ago

BDR International

CA
Other transport equipment (35)
Updated 2 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers